Although Feng et al. reported that targeting epidermal growth factor receptor (EGFR) in a clinical trial showed a good response in EGFR-expressing advanced relapsed/refractory NSCLC, and Li et al. described that CAR-glypican 3 T cells displayed promising therapeutic effectiveness for the treatment of patients with lung squamous cell carcinoma, research regarding LUAD is still limited. The gene discussed is GPC3; the disease is non-small cell lung carcinoma.